Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | MNPR | Common Stock | Options Exercise | +1.94K | +9.82% | 21.7K | Jan 1, 2022 | Direct | F1 | ||
transaction | MNPR | Common Stock | Tax liability | -$2.15K | -671 | -3.1% | $3.21 | 21K | Jan 1, 2022 | Direct | |
holding | MNPR | Common Stock | 4.11M | Jan 1, 2022 | See footnote | F2 | |||||
holding | MNPR | Common Stock | 167K | Jan 1, 2022 | See footnote | F3 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | MNPR | Restricted Stock Units | Options Exercise | $0 | -1.94K | -33.33% | $0.00 | 3.87K | Jan 1, 2022 | Common Stock | 1.94K | Direct | F1, F4 |
Id | Content |
---|---|
F1 | Represents shares acquired on vesting and settlement of restricted stock units. |
F2 | This is based upon the 4,111,272.88 shares of Monopar Common Stock that Tactic Pharma LLC indirectly controls through TacticGem LLC. As a manager of Tactic Pharma LLC, Dr. Mazar may be deemed to share voting and dispositive power over these 4,111,272.88 shares. Dr. Mazar disclaims beneficial ownership of the 4,111,272.88 shares held by Tactic Pharma LLC, except to the extent of his pecuniary interest therein. |
F3 | This is based upon the 166,667 shares of Monopar Common Stock that Tactic Pharma LLC directly owns. As a manager of Tactic Pharma LLC, Dr. Mazar may be deemed to share voting and dispositive power over these 166,667 shares. Dr. Mazar disclaims beneficial ownership of the 166,667 shares held by Tactic Pharma LLC, except to the extent of his pecuniary interest therein. |
F4 | On January 31, 2020 the reporting person was granted 7,748 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. |